We review drug conjugates combining a tumor-selective moiety with a cytotoxic agent as
cancer treatments. Currently, antibody-drug conjugates (ADCs) are the most common drug …

The mercapturic acid pathway is a major route for the biotransformation of xenobiotic and
endobiotic electrophilic compounds and their metabolites. Mercapturic acids (N-acetyl-l …

PURPOSE Melphalan flufenamide (melflufen) is a first-in-class peptide-drug conjugate that
targets aminopeptidases and rapidly and selectively releases alkylating agents into tumor …

Background Melphalan flufenamide (melflufen), an alkylating peptide-drug conjugate, plus
dexamethasone showed clinical activity and manageable safety in the phase 2 HORIZON …

Background Multiple myeloma is an incurable haematological malignancy, representing
over 10% of haematological cancers in the USA. We did a phase 1–2 study of melflufen and …

From the medical, pharmaceutical, and social perspectives, 2021 has been a year
dominated by the COVID-19 pandemic. However, despite this global health crisis, the …

In October 2021, melphalan flufenamide (melflufen) was withdrawn from the US market for
the treatment of multiple myeloma. The decision occurred based on results from a phase 3 …

Despite the significant progress in anticancer drug development over recent years, there is a
vital need for newer agents with unique, but still effective, mechanisms of action in order to …

Despite the availability of new therapies that have led to improved outcomes for patients with
multiple myeloma, most patients will eventually relapse. With triplet and even quadruplet …

Simple Summary The aims of this study were to investigate aminopeptidase expression in
multiple myeloma and to identify the aminopeptidases responsible for the activation of the …